Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Read the original at statnews.com →

More in Health & Medicine

More from Friday 9 October →